NEXT BIOMETRICS GROUP AS (NEXT.OL) Stock Fundamental Analysis

OSL:NEXT • NO0010629108

0.914 NOK
+0.02 (+2.7%)
Last: Mar 3, 2026, 09:49 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NEXT. NEXT was compared to 51 industry peers in the Electronic Equipment, Instruments & Components industry. NEXT has a bad profitability rating. Also its financial health evaluation is rather negative. NEXT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NEXT has reported negative net income.
  • NEXT had a negative operating cash flow in the past year.
  • In the past 5 years NEXT always reported negative net income.
  • NEXT had a negative operating cash flow in each of the past 5 years.
NEXT.OL Yearly Net Income VS EBIT VS OCF VS FCFNEXT.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • NEXT's Return On Assets of -140.57% is on the low side compared to the rest of the industry. NEXT is outperformed by 94.12% of its industry peers.
  • NEXT's Return On Equity of -252.42% is on the low side compared to the rest of the industry. NEXT is outperformed by 90.20% of its industry peers.
Industry RankSector Rank
ROA -140.57%
ROE -252.42%
ROIC N/A
ROA(3y)-41%
ROA(5y)-47.51%
ROE(3y)-52%
ROE(5y)-61.09%
ROIC(3y)N/A
ROIC(5y)N/A
NEXT.OL Yearly ROA, ROE, ROICNEXT.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • NEXT has a Gross Margin of 42.52%. This is comparable to the rest of the industry: NEXT outperforms 52.94% of its industry peers.
  • NEXT's Gross Margin has improved in the last couple of years.
  • NEXT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y45.73%
GM growth 5Y17.56%
NEXT.OL Yearly Profit, Operating, Gross MarginsNEXT.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NEXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NEXT has more shares outstanding than it did 1 year ago.
  • NEXT has more shares outstanding than it did 5 years ago.
  • NEXT has a worse debt/assets ratio than last year.
NEXT.OL Yearly Shares OutstandingNEXT.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NEXT.OL Yearly Total Debt VS Total AssetsNEXT.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.98, we must say that NEXT is in the distress zone and has some risk of bankruptcy.
  • NEXT's Altman-Z score of -4.98 is on the low side compared to the rest of the industry. NEXT is outperformed by 90.20% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that NEXT is not too dependend on debt financing.
  • NEXT has a better Debt to Equity ratio (0.03) than 88.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -4.98
ROIC/WACCN/A
WACC8.43%
NEXT.OL Yearly LT Debt VS Equity VS FCFNEXT.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

2.3 Liquidity

  • A Current Ratio of 2.08 indicates that NEXT has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.08, NEXT is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
  • NEXT has a Quick Ratio of 2.08. This is a bad value and indicates that NEXT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NEXT has a worse Quick ratio (0.64) than 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 0.64
NEXT.OL Yearly Current Assets VS Current LiabilitesNEXT.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for NEXT have decreased strongly by -98.85% in the last year.
  • NEXT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -71.79%.
  • The Revenue has been decreasing by -3.25% on average over the past years.
EPS 1Y (TTM)-98.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1214.4%
Revenue 1Y (TTM)-71.79%
Revenue growth 3Y12.14%
Revenue growth 5Y-3.25%
Sales Q2Q%-89.13%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NEXT.OL Yearly Revenue VS EstimatesNEXT.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NEXT.OL Yearly EPS VS EstimatesNEXT.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NEXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEXT.OL Price Earnings VS Forward Price EarningsNEXT.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEXT.OL Per share dataNEXT.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NEXT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEXT BIOMETRICS GROUP AS

OSL:NEXT (3/3/2026, 9:49:16 AM)

0.914

+0.02 (+2.7%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)11-19
Earnings (Next)03-11
Inst Owners14.24%
Inst Owner ChangeN/A
Ins Owners7.13%
Ins Owner ChangeN/A
Market Cap109.55M
Revenue(TTM)20.59M
Net Income(TTM)-78.80M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.32
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 3.73
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.17
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -140.57%
ROE -252.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.52%
FCFM N/A
ROA(3y)-41%
ROA(5y)-47.51%
ROE(3y)-52%
ROE(5y)-61.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y45.73%
GM growth 5Y17.56%
F-Score1
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.68%
Cap/Sales 8.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 0.64
Altman-Z -4.98
F-Score1
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)4.07%
Cap/Depr(5y)3.14%
Cap/Sales(3y)0.34%
Cap/Sales(5y)0.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1214.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-71.79%
Revenue growth 3Y12.14%
Revenue growth 5Y-3.25%
Sales Q2Q%-89.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-117.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-78.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.41%
OCF growth 3YN/A
OCF growth 5YN/A

NEXT BIOMETRICS GROUP AS / NEXT.OL FAQ

What is the ChartMill fundamental rating of NEXT BIOMETRICS GROUP AS (NEXT.OL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NEXT.OL.


Can you provide the valuation status for NEXT BIOMETRICS GROUP AS?

ChartMill assigns a valuation rating of 0 / 10 to NEXT BIOMETRICS GROUP AS (NEXT.OL). This can be considered as Overvalued.


How profitable is NEXT BIOMETRICS GROUP AS (NEXT.OL) stock?

NEXT BIOMETRICS GROUP AS (NEXT.OL) has a profitability rating of 1 / 10.